Ole Petter Rekvig
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ole Petter Rekvig has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
- George C. Tsokos
Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
1 shared publication
Latest Publications
- 7 July 2026
- Published by Elsevier in Autoimmunity Reviews
- Vol. 25 (10) , 104138
Reflections on chromatin structures, corresponding autoantibodies – And conflicting dogmas impacting pathogenesis of lupus nephritis
- 7 July 2026
- Published by Elsevier in Autoimmunity Reviews
- Vol. 25 (10) , 104138
Reflections on chromatin structures, corresponding autoantibodies – And conflicting dogmas impacting pathogenesis of lupus nephritis
- 31 January 2026
- Published by Elsevier in Autoimmunity Reviews
- Vol. 25 (3) , 103990
Causation-based SLE diagnostic criteria should replace advance-repressing SLE classification criteria
- 31 January 2026
- Published by Elsevier in Autoimmunity Reviews
- Vol. 25 (3) , 103990
Causation-based SLE diagnostic criteria should replace advance-repressing SLE classification criteria
- Open Access
- 24 July 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1580664
Philosophical and distinct SLE epitomes: dogmas in conflict with evidences and an intellectual dissonance between established pathophysiological models
This study centers around dogmas, their identifications and definitions, and their impact on our understanding of what Systemic lupus erythematosus (SLE) is. A focus is centered on description of how we investigate this enigmatic syndrome, and how we try to describe processual elements that can be targeted by experimental therapy modalities. Mostly, this study deals with definitions and critical insight into how dogmas hinder our understanding of SLE. When we start to investigate apparently convincing statements related to SLE, it is surprising how many of them are uncovered as authoritative, but not founded by concrete evidence! This problem refers to a definition of a dogma: A point of view or tenet put forth as authoritative without adequate grounds or evidence (Merriam-Webster). For example, several central statements/criteria are revealed as dogmas that challenge our insight into SLE as a complex syndrome. Critical in this context is the immense impact of “SLE classification criteria” versions in relation to evidence-based basic SLE processes. The SLE classification criteria will, as described in this study, most probably not identify SLE as “a one disease entity,” but more likely as a “poly-causal, poly-etiological, and poly-phenotypic “theoretical template SLE,” “SLE-like,” or “SLE-like non-SLE” syndromes. This is problematic as SLE may, in context of definitions described here, not be rationally structured by classification criteria. This prevents SLE cohorts from being suitable and ideal as study objects aimed to investigate experimental therapy modalities, genetics, etiology, and pathophysiology. However, this pessimistic view may turn into optimism if dogmas described in this study are identified and subjected to causal studies based on critical hypotheses. Today’s interpretative use of SLE classification criteria tentatively maintains a narrative that describes scientific studies of the SLE syndrome as not optimal and not ideal.
- 24 July 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1580664
Open AccessPhilosophical and distinct SLE epitomes: dogmas in conflict with evidences and an intellectual dissonance between established pathophysiological models
This study centers around dogmas, their identifications and definitions, and their impact on our understanding of what Systemic lupus erythematosus (SLE) is. A focus is centered on description of how we investigate this enigmatic syndrome, and how we try to describe processual elements that can be targeted by experimental therapy modalities. Mostly, this study deals with definitions and critical insight into how dogmas hinder our understanding of SLE. When we start to investigate apparently convincing statements related to SLE, it is surprising how many of them are uncovered as authoritative, but not founded by concrete evidence! This problem refers to a definition of a dogma: A point of view or tenet put forth as authoritative without adequate grounds or evidence (Merriam-Webster). For example, several central statements/criteria are revealed as dogmas that challenge our insight into SLE as a complex syndrome. Critical in this context is the immense impact of “SLE classification criteria” versions in relation to evidence-based basic SLE processes. The SLE classification criteria will, as described in this study, most probably not identify SLE as “a one disease entity,” but more likely as a “poly-causal, poly-etiological, and poly-phenotypic “theoretical template SLE,” “SLE-like,” or “SLE-like non-SLE” syndromes. This is problematic as SLE may, in context of definitions described here, not be rationally structured by classification criteria. This prevents SLE cohorts from being suitable and ideal as study objects aimed to investigate experimental therapy modalities, genetics, etiology, and pathophysiology. However, this pessimistic view may turn into optimism if dogmas described in this study are identified and subjected to causal studies based on critical hypotheses. Today’s interpretative use of SLE classification criteria tentatively maintains a narrative that describes scientific studies of the SLE syndrome as not optimal and not ideal.
- Open Access
- 28 January 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1507792
Why is it so difficult to understand why we don’t understand human systemic lupus erythematosus? Contemplating facts, conflicts, and impact of “the causality cascade paradigm”
In attempts to understand systemic lupus erythematosus (SLE), we find ourselves in the intellectual cross-point between nosology, pathogenicity-oriented science, philosophy, empiricism, and qualified conjectures. A vital consequence in science theory is that scientific hypotheses that are not critically investigated are in danger of being transformed into scientific dogmas1. This statement has consequences for this study. Two central problematic aspects are discussed. For the first, we have to consider new selection principles for classification criteria—implying integration of the causality principle. Second, central historical data must be implemented if we aim to understand SLE. These data comprise famous descriptions of distinct, dynamically changing DNA structures linked to the genetic machinery. These unique structures have since their discoveries decades ago mostly been ignored in SLE research. Likewise, inconclusive dogmatic data indicate that different glomerular ligands are recognized by nephritogenic anti-dsDNA antibodies—exposed chromatin fragments or inherent membrane ligands. These incongruent models have not been comparatively and systematically investigated. Three research areas will be critically discussed: (i) selection and role of SLE classification criteria, a process that must imply the causality principle; (ii) definition and impact of anti-dsDNA structure-specific antibodies; (iii) incongruent pathogenic models that account for lupus nephritis. A precise and critically important question is if SLE itself is a response to a dominant unified cause that initiates a cascade of downstream effects (criteria) or if SLE represents combined responses to a random interplay of multiple cause-effect events. These principally different explanations are formally not excluded or accepted today. Currently, SLE may be regarded as a disease with phenotypic diversity, independently segregated manifestations with unresolved etiologies that are not unique to a single SLE phenotype. The focus for the present discussion is basically how we, by critical hypotheses, can re-consider science-based selection of SLE classification criteria in order to delimitate and rationalize SLE. Classification criteria, autoimmunity, DNA structures, and anti-dsDNA antibodies are integrated aspects in this discussion.
- 28 January 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1507792
Open AccessWhy is it so difficult to understand why we don’t understand human systemic lupus erythematosus? Contemplating facts, conflicts, and impact of “the causality cascade paradigm”
In attempts to understand systemic lupus erythematosus (SLE), we find ourselves in the intellectual cross-point between nosology, pathogenicity-oriented science, philosophy, empiricism, and qualified conjectures. A vital consequence in science theory is that scientific hypotheses that are not critically investigated are in danger of being transformed into scientific dogmas1. This statement has consequences for this study. Two central problematic aspects are discussed. For the first, we have to consider new selection principles for classification criteria—implying integration of the causality principle. Second, central historical data must be implemented if we aim to understand SLE. These data comprise famous descriptions of distinct, dynamically changing DNA structures linked to the genetic machinery. These unique structures have since their discoveries decades ago mostly been ignored in SLE research. Likewise, inconclusive dogmatic data indicate that different glomerular ligands are recognized by nephritogenic anti-dsDNA antibodies—exposed chromatin fragments or inherent membrane ligands. These incongruent models have not been comparatively and systematically investigated. Three research areas will be critically discussed: (i) selection and role of SLE classification criteria, a process that must imply the causality principle; (ii) definition and impact of anti-dsDNA structure-specific antibodies; (iii) incongruent pathogenic models that account for lupus nephritis. A precise and critically important question is if SLE itself is a response to a dominant unified cause that initiates a cascade of downstream effects (criteria) or if SLE represents combined responses to a random interplay of multiple cause-effect events. These principally different explanations are formally not excluded or accepted today. Currently, SLE may be regarded as a disease with phenotypic diversity, independently segregated manifestations with unresolved etiologies that are not unique to a single SLE phenotype. The focus for the present discussion is basically how we, by critical hypotheses, can re-consider science-based selection of SLE classification criteria in order to delimitate and rationalize SLE. Classification criteria, autoimmunity, DNA structures, and anti-dsDNA antibodies are integrated aspects in this discussion.
- Open Access
- 4 June 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1393814
SLE: a cognitive step forward—a synthesis of rethinking theories, causality, and ignored DNA structures
Systemic lupus erythematosus (SLE) is classified by instinctual classification criteria. A valid proclamation is that these formally accepted SLE classification criteria legitimate the syndrome as being difficult to explain and therefore enigmatic. SLE involves scientific problems linked to etiological factors and criteria. Our insufficient understanding of the clinical condition uniformly denoted SLE depends on the still open question of whether SLE is, according to classification criteria, a well-defined one disease entity or represents a variety of overlapping indistinct syndromes. Without rational hypotheses, these problems harm clear definition(s) of the syndrome. Why SLE is not anchored in logic, consequent, downstream interdependent and interactive inflammatory networks may rely on ignored predictive causality principles. Authoritative classification criteria do not reflect consequent causality criteria and do not unify characterization principles such as diagnostic criteria. We need now to reconcile legendary scientific achievements to concretize the delimitation of what SLE really is. Not all classified SLE syndromes are “genuine SLE”; many are theoretically “SLE-like non-SLE” syndromes. In this study, progressive theories imply imperative challenges to reconsider the fundamental impact of “the causality principle”. This may offer us logic classification and diagnostic criteria aimed at identifying concise SLE syndromes as research objects. Can a systems science approach solve this problem?
- 4 June 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1393814
Open AccessSLE: a cognitive step forward—a synthesis of rethinking theories, causality, and ignored DNA structures
Systemic lupus erythematosus (SLE) is classified by instinctual classification criteria. A valid proclamation is that these formally accepted SLE classification criteria legitimate the syndrome as being difficult to explain and therefore enigmatic. SLE involves scientific problems linked to etiological factors and criteria. Our insufficient understanding of the clinical condition uniformly denoted SLE depends on the still open question of whether SLE is, according to classification criteria, a well-defined one disease entity or represents a variety of overlapping indistinct syndromes. Without rational hypotheses, these problems harm clear definition(s) of the syndrome. Why SLE is not anchored in logic, consequent, downstream interdependent and interactive inflammatory networks may rely on ignored predictive causality principles. Authoritative classification criteria do not reflect consequent causality criteria and do not unify characterization principles such as diagnostic criteria. We need now to reconcile legendary scientific achievements to concretize the delimitation of what SLE really is. Not all classified SLE syndromes are “genuine SLE”; many are theoretically “SLE-like non-SLE” syndromes. In this study, progressive theories imply imperative challenges to reconsider the fundamental impact of “the causality principle”. This may offer us logic classification and diagnostic criteria aimed at identifying concise SLE syndromes as research objects. Can a systems science approach solve this problem?
- Open Access
- 1 February 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1346619
The greatest contribution to medical science is the transformation from studying symptoms to studying their causes—the unrelenting legacy of Robert Koch and Louis Pasteur—and a causality perspective to approach a definition of SLE
The basic initiative related to this study is derived from the fact that systemic lupus erythematosus (SLE) is a unique and fertile system science subject. We are, however, still far from understanding its nature. It may be fair to indicate that we are spending more time and resources on studying the complexity of classified SLE than studying the validity of classification criteria. This study represents a theoretical analysis of current instinctual1 SLE classification criteria based on “the causality principle.” The discussion has its basis on the radical scientific traditions introduced by Robert Koch and Louis Pasteur. They announced significant changes in our thinking of disease etiology through the implementation of the modern version of “the causality principle.” They influenced all aspects of today’s medical concepts and research: the transformation of medical science from studies of symptoms to study their causes, relevant for monosymptomatic diseases as for syndromes. Their studies focused on bacteria as causes of infectious diseases and on how the immune system adapts to control and prevent contagious spreading. This is the most significant paradigm shift in the modern history of medicine and resulted in radical changes in our view of the immune system. They described acquired post-infection immunity and active immunization by antigen-specific vaccines. The paradigm “transformation” has a great theoretical impact also on current studies of autoimmune diseases like SLE: symptoms and their cause(s). In this study, the evolution of SLE classification and diagnostic criteria is discussed from “the causality principle” perspective, and if contemporary SLE classification criteria are as useful as believed today for SLE research. This skepticism is based on the fact that classification criteria are not selected based on cogent causal strategies. The SLE classification criteria do not harmonize with Koch’s and Pasteur’s causality principle paradigms and not with Witebsky’s Koch-derived postulates for autoimmune and infectious diseases. It is not established whether the classification criteria can separate SLE as a “one disease entity” from “SLE-like non-SLE disorders”—the latter in terms of SLE imitations. This is discussed here in terms of weight, rank, and impact of the classification criteria: Do they all originate from “one basic causal etiology”? Probably not.
- 1 February 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1346619
Open AccessThe greatest contribution to medical science is the transformation from studying symptoms to studying their causes—the unrelenting legacy of Robert Koch and Louis Pasteur—and a causality perspective to approach a definition of SLE
The basic initiative related to this study is derived from the fact that systemic lupus erythematosus (SLE) is a unique and fertile system science subject. We are, however, still far from understanding its nature. It may be fair to indicate that we are spending more time and resources on studying the complexity of classified SLE than studying the validity of classification criteria. This study represents a theoretical analysis of current instinctual1 SLE classification criteria based on “the causality principle.” The discussion has its basis on the radical scientific traditions introduced by Robert Koch and Louis Pasteur. They announced significant changes in our thinking of disease etiology through the implementation of the modern version of “the causality principle.” They influenced all aspects of today’s medical concepts and research: the transformation of medical science from studies of symptoms to study their causes, relevant for monosymptomatic diseases as for syndromes. Their studies focused on bacteria as causes of infectious diseases and on how the immune system adapts to control and prevent contagious spreading. This is the most significant paradigm shift in the modern history of medicine and resulted in radical changes in our view of the immune system. They described acquired post-infection immunity and active immunization by antigen-specific vaccines. The paradigm “transformation” has a great theoretical impact also on current studies of autoimmune diseases like SLE: symptoms and their cause(s). In this study, the evolution of SLE classification and diagnostic criteria is discussed from “the causality principle” perspective, and if contemporary SLE classification criteria are as useful as believed today for SLE research. This skepticism is based on the fact that classification criteria are not selected based on cogent causal strategies. The SLE classification criteria do not harmonize with Koch’s and Pasteur’s causality principle paradigms and not with Witebsky’s Koch-derived postulates for autoimmune and infectious diseases. It is not established whether the classification criteria can separate SLE as a “one disease entity” from “SLE-like non-SLE disorders”—the latter in terms of SLE imitations. This is discussed here in terms of weight, rank, and impact of the classification criteria: Do they all originate from “one basic causal etiology”? Probably not.
- Open Access
- 24 October 2023
- Published by Elsevier in Autoimmunity Reviews
- Vol. 22 (12) , 103470
SLE classification criteria: Is “The causality principle” integrated and operative – and do the molecular and genetical network, on which criteria depend on, support the definition of SLE as “a one disease entity” – A theoretical discussion
- 24 October 2023
- Published by Elsevier in Autoimmunity Reviews
- Vol. 22 (12) , 103470
Open AccessSLE classification criteria: Is “The causality principle” integrated and operative – and do the molecular and genetical network, on which criteria depend on, support the definition of SLE as “a one disease entity” – A theoretical discussion
- Open Access
- 28 September 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 1011591
SLE classification criteria: Science-based icons or algorithmic distractions – an intellectually demanding dilemma
It is, so to say, not a prerogative authority assigned to SLE classification criteria that allow them to declare something definitively important about SLE. This is particularly true as criteria-based classification processes overrule the highly needed evolution of concise diagnostic criteria. It is classification criteria that allocate SLE patients into cohorts intended to describe the nature of their disease. Therefore, all major SLE classification criteria since the 1971 preliminary criteria usurp the role of diagnostic criteria. Today´s practice silently accept that the SLE classification process “diagnose” SLE patients despite the fact that classification criteria are not accepted as diagnostic criteria! This is a central paradox in contemporary SLE research strategies. Contemporary SLE cohorts are designed to investigate SLE´s etiological features. However, each cohort that is categorized by classification criteria has one central inherent problem. From theoretical and practical arguments, they embody multiple distinct clinical phenotypes. This raises the critical and principal question if phenotypically heterogenic SLE cohorts are useful to identify basic SLE-specific etiology(ies) and disease process(es). In times to come, we must prioritize development of firm diagnostic criteria for SLE, as the classification criteria have not contributed to reduce the enigmatic character of the syndrome. No radical improvements are visible in the horizon that may lead to concise investigations of SLE in well-defined homogenous SLE cohorts. We must develop new strategies where studies of phenotypically standardized cohorts of SLE must be central elements. Problems related to contemporary SLE classification criteria are contemplated, analyzed, and critically discussed in this study.
- 28 September 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 1011591
Open AccessSLE classification criteria: Science-based icons or algorithmic distractions – an intellectually demanding dilemma
It is, so to say, not a prerogative authority assigned to SLE classification criteria that allow them to declare something definitively important about SLE. This is particularly true as criteria-based classification processes overrule the highly needed evolution of concise diagnostic criteria. It is classification criteria that allocate SLE patients into cohorts intended to describe the nature of their disease. Therefore, all major SLE classification criteria since the 1971 preliminary criteria usurp the role of diagnostic criteria. Today´s practice silently accept that the SLE classification process “diagnose” SLE patients despite the fact that classification criteria are not accepted as diagnostic criteria! This is a central paradox in contemporary SLE research strategies. Contemporary SLE cohorts are designed to investigate SLE´s etiological features. However, each cohort that is categorized by classification criteria has one central inherent problem. From theoretical and practical arguments, they embody multiple distinct clinical phenotypes. This raises the critical and principal question if phenotypically heterogenic SLE cohorts are useful to identify basic SLE-specific etiology(ies) and disease process(es). In times to come, we must prioritize development of firm diagnostic criteria for SLE, as the classification criteria have not contributed to reduce the enigmatic character of the syndrome. No radical improvements are visible in the horizon that may lead to concise investigations of SLE in well-defined homogenous SLE cohorts. We must develop new strategies where studies of phenotypically standardized cohorts of SLE must be central elements. Problems related to contemporary SLE classification criteria are contemplated, analyzed, and critically discussed in this study.
- Open Access
- 11 January 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12, 808008
The Anti-DNA Antibodies: Their Specificities for Unique DNA Structures and Their Unresolved Clinical Impact—A System Criticism and a Hypothesis
Systemic lupus erythematosus (SLE) is diagnosed and classified by criteria, or by experience, intuition and traditions, and not by scientifically well-defined etiology(ies) or pathogenicity(ies). One central criterion and diagnostic factor is founded on theoretical and analytical approaches based on our imperfect definition of the term “The anti-dsDNA antibody”. “The anti-dsDNA antibody” holds an archaic position in SLE as a unique classification criterium and pathogenic factor. In a wider sense, antibodies to unique transcriptionally active or silent DNA structures and chromatin components may have individual and profound nephritogenic impact although not considered yet – not in theoretical nor in descriptive or experimental contexts. This hypothesis is contemplated here. In this analysis, our state-of-the-art conception of these antibodies is probed and found too deficient with respect to their origin, structural DNA specificities and clinical/pathogenic impact. Discoveries of DNA structures and functions started with Miescher’s Nuclein (1871),viaChargaff, Franklin, Watson and Crick, and continues today. The discoveries have left us with a DNA helix that presents distinct structures expressing unique operations of DNA. All structures are proven immunogenic! Unique autoimmune antibodies are described against e.g. ssDNA, elongated B DNA, bent B DNA, Z DNA, cruciform DNA, or individual components of chromatin. In light of the massive scientific interest in anti-DNA antibodies over decades, it is an unexpected observation that the spectrum of DNA structures has been known for decades without being implemented in clinical immunology. This leads consequently to a critical analysis of historical and contemporary evidence-based data and of ignored and one-dimensional contexts and hypotheses: i.e. “one antibody - one disease”. In this study radical viewpoints on the impact of DNA and chromatin immunity/autoimmunity are considered and discussed in context of the pathogenesis of lupus nephritis.
- 11 January 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12, 808008
Open AccessThe Anti-DNA Antibodies: Their Specificities for Unique DNA Structures and Their Unresolved Clinical Impact—A System Criticism and a Hypothesis
Systemic lupus erythematosus (SLE) is diagnosed and classified by criteria, or by experience, intuition and traditions, and not by scientifically well-defined etiology(ies) or pathogenicity(ies). One central criterion and diagnostic factor is founded on theoretical and analytical approaches based on our imperfect definition of the term “The anti-dsDNA antibody”. “The anti-dsDNA antibody” holds an archaic position in SLE as a unique classification criterium and pathogenic factor. In a wider sense, antibodies to unique transcriptionally active or silent DNA structures and chromatin components may have individual and profound nephritogenic impact although not considered yet – not in theoretical nor in descriptive or experimental contexts. This hypothesis is contemplated here. In this analysis, our state-of-the-art conception of these antibodies is probed and found too deficient with respect to their origin, structural DNA specificities and clinical/pathogenic impact. Discoveries of DNA structures and functions started with Miescher’s Nuclein (1871),viaChargaff, Franklin, Watson and Crick, and continues today. The discoveries have left us with a DNA helix that presents distinct structures expressing unique operations of DNA. All structures are proven immunogenic! Unique autoimmune antibodies are described against e.g. ssDNA, elongated B DNA, bent B DNA, Z DNA, cruciform DNA, or individual components of chromatin. In light of the massive scientific interest in anti-DNA antibodies over decades, it is an unexpected observation that the spectrum of DNA structures has been known for decades without being implemented in clinical immunology. This leads consequently to a critical analysis of historical and contemporary evidence-based data and of ignored and one-dimensional contexts and hypotheses: i.e. “one antibody - one disease”. In this study radical viewpoints on the impact of DNA and chromatin immunity/autoimmunity are considered and discussed in context of the pathogenesis of lupus nephritis.